Perennial Advisors’s AstraZeneca AZN Stock Holding History

Perennial Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,400	Closed	-$200K	–	109
2023 Q2	$200K	Buy	+1,400	New	+$206K	0.05%	111

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Perennial Advisors's AZN Position: Q3 2023 in Review

Perennial Advisors sold out of AstraZeneca (AZN) in Q3 2023, closing a stake of 1,400 shares — an estimated $200K sold.

Perennial Advisors first reported a position in AZN in Q2 2023 and held it in 1 quarter. The position peaked at $200K in Q2 2023. 1,074 funds tracked by Wall St. Rank hold AZN as of Q3 2023.

Perennial Advisors reported no remaining AstraZeneca position as of Q3 2023 after selling out during the quarter.
Perennial Advisors sold 1,400 AstraZeneca shares in Q3 2023, an estimated $200K.
Perennial Advisors first reported a position in AstraZeneca in Q2 2023 and held it in 1 quarter.
Perennial Advisors's AstraZeneca position peaked at $200K in Q2 2023.
1,074 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2023.

Based on Perennial Advisors's 13F filing for Q3 2023, filed 17 Oct 2023.